Effect of supplementation in treatment of women with polycystic ovary syndrome

Clinical trial of the effect of probiotic supplementation compared with the placebo on profiles of metabolic in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201704235623N112

Enrollment

Registered

2017-04-27

Start date

2017-02-28

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Probiotic capsule containing three strains of Lactobacillus acidophilus (2×109 CFU/g), Lactobacillus casei (2×109 CFU/g) and Bifidobacterium bifidum (2×109 CFU/g) (

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria Aged 18 to 40 years Obtaining informed consent

Exclusion criteria

Exclusion criteria: Smokers Taking probiotic supplements Pregnant women Endocrine diseases including thyroid, diabetes and/or impaired glucose tolerance.

Design outcomes

Primary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total testosterone. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;SHBG. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;DHEAS. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Hirsutism. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical observation.	—

Measure

Time frame

Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total testosterone. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;SHBG. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;DHEAS. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Hirsutism. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Clinical observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Karamali

Iran University of Medical Sciences

karamali.maryam2@gmail.com+98 86 1278 0660

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026